Schneider, Charlotte A., Tager, Philipp, Hammes, Jochen, Fischer, Thomas, Drzezga, Alexander, Pfister, David, Heidenreich, Axel and Schmidt, Matthias (2022). Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin, 61 (1). S. 25 - 33. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2567-6407
Full text not available from this repository.Abstract
Objective To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods Between November 2014 and December 2018, a total of 56 consecutive patients (median age 69.5 years; range 55-84 years) with mCRPC were included in this retrospective analysis. Patients received between 1 and 4 therapy cycles with a mean activity of 6.8 GBq per cycle. Biochemical response was evaluated using Prostate Cancer Working Group Criteria 3 (PCWG 3). Survival was assessed using Kaplan-Meier estimates and Cox proportional hazards regression analysis. This retrospective study was approved by the local ethics committee. Results A total of 139 treatment cycles with Lu-177-PSMA-617 were performed. A decline of 50% or more of prostate-specific antigen (PSA) level occurred in 54% and a PSA decline of any amount in 65% of patients. The estimated median overall survival (OS) was 16 months, in the chemotherapy subgroup 14 months. A longer OS was associated with a PSA-decline >= 50%, more than 2 cycles of therapy, cumulative activity >15 GBq and an initial alkaline phosphatase <= 220 [U/l]. These identified predictors remained significant on uni- and multivariate Cox regression analysis. Moreover, 40% of the patients who were non-responders after the first therapy cycle turned into responders after the second one. Conclusion PSA-decline >= 50%, a cumulative activity >15 GBq and an initial alkaline phosphatase <= 220 [U/l] were identified as key predictors of prolonged OS in patients with mCRPC. In contrast rapid clinical deterioration mostly due to skeletal carcinomatosis resulted in early treatment failure.
| Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||
| Creators: |
|
||||||||||||||||||||||||||||||||||||
| URN: | urn:nbn:de:hbz:38-562730 | ||||||||||||||||||||||||||||||||||||
| DOI: | 10.1055/a-1670-9500 | ||||||||||||||||||||||||||||||||||||
| Journal or Publication Title: | Nuklearmedizin | ||||||||||||||||||||||||||||||||||||
| Volume: | 61 | ||||||||||||||||||||||||||||||||||||
| Number: | 1 | ||||||||||||||||||||||||||||||||||||
| Page Range: | S. 25 - 33 | ||||||||||||||||||||||||||||||||||||
| Date: | 2022 | ||||||||||||||||||||||||||||||||||||
| Publisher: | GEORG THIEME VERLAG KG | ||||||||||||||||||||||||||||||||||||
| Place of Publication: | STUTTGART | ||||||||||||||||||||||||||||||||||||
| ISSN: | 2567-6407 | ||||||||||||||||||||||||||||||||||||
| Language: | English | ||||||||||||||||||||||||||||||||||||
| Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||
| Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||
| Subjects: | no entry | ||||||||||||||||||||||||||||||||||||
| Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/56273 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |